FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC
A breakthrough therapy designation has been granted for sacituzumab tirumotecan by the FDA for patients with NSCLC.The Food and Drug ...
Tag: non-small cell lung cancer
Resistance Mechanisms May Steer Therapy Sequences in EGFR-Mutated Lung Cancer
Recent advances in the lung cancer space have expanded the available treatment options for patients with non-small cell lung cancer ...
FDA Approves Presurgical, Postsurgical Opdivo for NSCLC
The FDA has approved Opdivo as a presurgical and postsurgical treatment for some patients with non-small cell lung cancer. The ...
Telehealth Palliative Care Comparable to In-Person Visits
Opting for palliative care via telehealth may be more convenient and just as effective as in-person care. Image generated by ...
FDA Approves Tagrisso for Some With Advanced NSCLC
Tagrisso was approved by the FDA for certain patients with stage 3 non-small cell lung cancer.The Food and Drug Administration ...
Adaptive NSCLC Study Fails to Produce Improved Results, Clinical Benefits in Some
Long-term benefits were improved in some patients with advanced non-small cell lung cancer (NSCLC) enrolled in experimental combination groups, although ...
Rybrevant Plus Chemo Approved by FDA in Lung Cancer Subset
The FDA has approved Rybrevant plus chemotherapy for certain patients with locally advanced or metastatic non-small cell lung cancer, following ...
Imfinzi After Primary Treatment Does Not Improve Disease-Free Survival in PD-L1-Positive NSCLC
Imfinzi was not shown to improve disease-free survival in patients with PD-L1-positive NSCLC.Disease-free survival (DFS; time after diagnosis during which ...
FDA Approves Subcutaneous Tecentriq Formulation
FDA Approves Subcutaneous Tecentriq FormulationThe Food and Drug Administration (FDA) approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), a subcutaneous injection, for ...
Frontline Ivonescimab May Further Reduce Progression or Death Risk Versus Keytruda in NSCLC Subset
Frontline Ivonescimab May Further Reduce Progression or Death Risk Versus Keytruda in NSCLC SubsetFor patients with PD-L1-positive advanced non-small cell ...
Opdivo Before and After Surgery Lowers Risk of Recurrence or Death by 40% in NSCLC
Opdivo Before and After Surgery Lowers Risk of Recurrence or Death by 40% in NSCLCFor patients with resectable (removable by ...
First-Line Rybrevant Plus Lazcluze Shows Trend Toward Overall Survival in EGFR-Positive NSCLC
First-Line Rybrevant Plus Lazcluze Shows Trend Toward Overall Survival in EGFR-Positive NSCLCIn the first line of treatment, Rybrevant (amivantamab) plus ...